Cargando…

Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial

BACKGROUND: Insulin resistance and hyperinsulinemia in patients with type 2 diabetes (T2D) are adversely associated with the development and worsening of heart failure (HF). Herein, we sought to investigate the effect of canagliflozin on insulin concentrations and the associations of changes in insu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Atsushi, Imai, Takumi, Shimabukuro, Michio, Taguchi, Isao, Sezai, Akira, Toyoda, Shigeru, Watada, Hirotaka, Ako, Junya, Node, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358857/ https://www.ncbi.nlm.nih.gov/pubmed/35941584 http://dx.doi.org/10.1186/s12933-022-01589-3

Ejemplares similares

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2016)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
por: Sezai, Akira, et al.
Publicado: (2022)

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
por: Kusunose, Kenya, et al.
Publicado: (2021)

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
por: Sezai, Akira, et al.
Publicado: (2019)

Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study
por: Fujita, Yuko, et al.
Publicado: (2022)

Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019)

Does canagliflozin decrease natriuretic peptide levels in patients with diabetes and heart failure?
por: Martín, Ernesto, et al.
Publicado: (2022)

Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction
por: Ma, Sai, et al.
Publicado: (2022)

Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial
por: Tanaka, Atsushi, et al.
Publicado: (2021)

In‐hospital therapy for worsening heart failure: black box or sweet spot?
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
por: Rådholm, Karin, et al.
Publicado: (2018)

Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

Patterns in the Use of Heart Failure Telemonitoring: Post Hoc Analysis of the e-Vita Heart Failure Trial
por: Brons, Maaike, et al.
Publicado: (2023)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
por: Spertus, John A., et al.
Publicado: (2022)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure
por: Ikeda, Yuki, et al.
Publicado: (2021)

Prognostic value of cardio-hepatic-skeletal muscle syndrome in patients with heart failure
por: Noda, Takumi, et al.
Publicado: (2021)

Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study
por: Martín, Ernesto, et al.
Publicado: (2021)

Clinical Considerations When Introducing Sodium-Glucose Co-Transporter 2 Inhibition in Patients With Heart Failure
por: Yazaki, Mayu, et al.
Publicado: (2019)

Relationship between the spread of COVID-19, social frailty, and depressive symptoms in patients with heart failure
por: Shakuta, Saki, et al.
Publicado: (2022)

Prognostic Impact of Serum Albumin for Developing Heart Failure Remotely after Acute Myocardial Infarction
por: Yoshioka, Goro, et al.
Publicado: (2020)

Response to letter to the editor entitled “Association between left atrial sphericity index and clinical outcomes in patients with systolic heart failure”
por: Yazaki, Mayu, et al.
Publicado: (2021)

Relationship of normal-weight central obesity with the risk for heart failure and atrial fibrillation: analysis of a nationwide health check-up and claims database
por: Ueno, Kensuke, et al.
Publicado: (2022)

A Case of Fulminant Myocarditis With Preceding Repeated Episodes of Congestive Heart Failure
por: Tada, Yuko, et al.
Publicado: (2013)

Variation in heart rate range by 24‐h Holter monitoring predicts heart failure in patients with atrial fibrillation
por: Oikawa, Jun, et al.
Publicado: (2022)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Comparison of the prognostic values of three calculation methods for echocardiographic relative wall thickness in acute decompensated heart failure
por: Yamaguchi, Satoshi, et al.
Publicado: (2019)

Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2021)

Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
por: Ueda, Tomoya, et al.
Publicado: (2021)

The Usefulness of Prioritization of Ivabradine Before Beta-Blockers in a Heart Failure Patient Suffering From Intra-hemodialysis Hypotension
por: Yamaguchi, Satoshi, et al.
Publicado: (2023)

Sex Differences in Frequency of Instrumental Activities of Daily Living after Cardiac Rehabilitation and Its Impact on Outcomes in Patients with Heart Failure
por: Nozaki, Kohei, et al.
Publicado: (2022)

GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy
por: Shiraki, Aya, et al.
Publicado: (2019)

Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Advanced and Acute Heart Failure
por: Hyun, Junho, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_od05udkjn011cgh9a6cbg1dj04